Connect
MJA
MJA

Friedreich ataxia: from genes to therapies?

Martin B Delatycki, Panos A Ioannou and Andrew J Churchyard
Med J Aust 2005; 182 (9): . || doi: 10.5694/j.1326-5377.2005.tb06779.x
Published online: 2 May 2005

Most cases are caused by a single mutation, paving the way for therapeutic advances for this fatal disease

Friedreich ataxia (FRDA), an autosomal recessive disease, is the commonest of the inherited ataxias’, affecting around 1 in 30 000 people.1 With an average age of onset of 10 years, those affected by this condition become wheelchair-bound on average 10 years after onset. The symptom that heralds onset in the vast majority of cases is increasing incoordination. Onset after 30 years of age is rare. Death ensues, on average, 36 years after disease onset and is largely due to hypertrophic cardiomyopathy.2 Other sources of morbidity in FRDA include an increased incidence of diabetes mellitus, dysarthria, swallowing difficulties, scoliosis, optic atrophy, hearing loss and foot deformity.1


  • 1 Murdoch Childrens Research Institute, Melbourne, VIC.
  • 2 Monash Institute for Neurological Disease, Monash Medical Centre, Melbourne, VIC.


Correspondence: 

  • 1. Delatycki M, Williamson R, Forrest S. Friedreich ataxia: an overview. J Med Genet 2000; 37: 1-8.
  • 2. Voncken M, Ioannou P, Delatycki MB. Friedreich ataxia — update on pathogenesis and possible therapies. Neurogenetics 2004; 5: 1-8.
  • 3. Babcock M, Silva D, Oaks R, et al. Regulation of mitochondrial iron accumulation by Yfh 1p, a putative homolog of frataxin. Science 1997; 276: 1709-1712.
  • 4. Seznec H, Simon D, Bouton C, et al. Friedreich ataxia: the oxidative stress paradox. Hum Mol Genet 2004 Dec 22; [Epub ahead of print].
  • 5. Richardson DR. Friedreich’s ataxia: iron chelators that target the mitochondrion as a therapeutic strategy? Expert Opin Investig Drugs 2003; 12: 235-245.
  • 6. Lodi R, Hart PE, Rajagopalan B, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. Ann Neurol 2001; 49: 590-596.
  • 7. Mariotti C, Solari A, Torta D, et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003; 60: 1676-1679.
  • 8. Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 2001; 276: 4588-4596.
  • 9. Sarsero JP, Li L, Wardan H, et al. Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia. J Gene Med 2003; 5: 72-81.
  • 10. Lynch DR, Farmer JM, Balcer LJ, Wilson RB. Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol 2002; 59: 743-747.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.